Correction to: Hypertension Research (2022) 46:19–31 https://doi.org/10.1038/s41440-022-01036-6
The original version of this article incorrectly stated the dosage of 6-diazo-5-oxo-L-norleucine (DON) in animal studies. The unit of DON was incorrect; it should be 3 μg/g. There are three errors regarding units of DON in “DON administration study” in Methods, “DON administration reduces tissue O-GlcNAc levels and the MR protein levels in db/db mice” in Results and the caption of Fig. 5E.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41440-022-01036-6.
Rights and permissions
About this article
Cite this article
Jo, R., Shibata, H., Kurihara, I. et al. Correction: Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification. Hypertens Res 46, 814 (2023). https://doi.org/10.1038/s41440-023-01167-4
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41440-023-01167-4
This article is cited by
-
CASZ1: a promising factor modulating aldosterone biosynthesis and mineralocorticoid receptor activity
Hypertension Research (2023)
